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ABSTRACT
Background: Studies on the characteristics CD4+ and CD8+ in hepatitis C and their correlation with the 
severity of the disease have been rarely conducted. This study was aimed to obtain the mean difference between 
CD4+ and CD8+ count in liver to evaluate their correlation with fibrosis and necroinflammatory grades in 
chronic hepatitis C. 
Method: A cross-sectional study was conducted between March and July 2010 with 30 liver biopsies obtained 
from patients with non-B and non-HIV chronic hepatitis C who visited the Outpatient Clinic of Hepatology Unit 
at Cipto Mangunkusumo Hospital in January 2008–February 2010. Fibrosis and necroinflammatory grades 
were determined using METAVIR methods on liver biopsies. The mean values of CD4+ and CD8+ in portal 
tracts and hepatic lobules in liver biopsy specimens were evaluated. Statistical analysis was performed by using 
independent T-test and Spearman test. 
Results: There was a difference in mean CD4+ counts between portal tracts and the lobules (95% 
CI = 4.3-17.9; p = 0.002) and also differences in mean CD8+ counts in portal tracts and hepatic lobules (95% 
CI = 15.4-35.6; p < 0.001). There was no correlation between CD4+ and CD8+ counts, either in portal tracts 
or the lobules, and inflammatory grades as well as the liver fibrosis. 
Conclusion: CD4+ and CD8+ counts are greater in portal area compared to the hepatic lobules, with greater 
CD8+ counts than CD4+. However, both CD4+ and CD8+ counts are not correlated to the severity of liver damage. 
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 ABSTRAK
Latar belakang: Penelitian mengenai karakteristik sistem imun seluler terutama CD4+ dan CD8+ pada 
hepatitis C serta korelasi terhadap beratnya penyakit hepatitis C belum banyak dilakukan. Penelitian ini 
bertujuan untuk mendapatkan beda rerata antara hitung CD4+ dan CD8+ di portal dan lobulus hati serta untuk 
mengetahui korelasinya dengan derajat fibrosis dan nekroinflamasi hati pada hepatitis C kronik.
Metode: Penelitian ini merupakan studi potong lintang yang dilakukan antara bulan Maret-Juli 2010 pada 30 
sampel biopsi hati pasien dengan hepatitis C kronik non-B dan non-HIV yang berobat ke Poliklinik Hepatologi 
Rumah Sakit Cipto Mangunkusumo antara bulan Januari 2008-Februari 2010. Derajat fibrosis dan nekroinflamasi 
ditentukan dengan metode METAVIR dari biopsi hati. Rerata hitung CD4+ dan CD8+ di lima portal dan lima 
lobulus dinilai dari sediaan biopsi hati. Analisis statistik dilakukan dengan uji-T independen dan tes Spearman.
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Hasil: Terdapat perbedaan rerata hitung CD4+ di portal dan lobulus (CI 95 % = 4,3-17,9; p = 0,002) dan 
perbedaan rerata hitung CD8+ di portal dan lobulus (CI 95% = 15,4-35,6; p < 0,001). Tidak ada korelasi antara 
hitung CD4+ dan CD8+ di portal maupun lobulus dengan derajat nekroinflamasi dan fibrosis hati. 
Simpulan: Hitung CD4+ dan CD8+ lebih banyak berada di portal daripada lobulus hati dengan jumlah 
hitung CD8+ lebih banyak daripada CD4+, namun baik pada CD4+ dan CD8+ tidak terdapat korelasi dengan 
derajat kerusakan hati. Hitung limfosit T CD8+ dan CD4+ di portal dan lobulus hati tidak dapat dijadikan 
prediktor kerusakan hati.
Kata kunci: CD4+, CD8+, intrahepatik, hepatitis C kronik, METAVIR
INTRODUCTION 
World Health Organization (WHO) has regarded 
hepatitis C virus (HCV) as one of global public health 
problems and estimates that about 3% of world’s 
population, i.e. 170 million people have been infected 
with HCV.1 The prevalence of hepatitis C ranges from 
0.1-5% and varries associated with its geographical 
distribution. The lowest seroprevalence of hepatitis 
C is found in Europe and the prevalence is about 1% 
and the highest seropravelence is found in Africa, 
about 5.3%.1 
In the United States, HCV accounts for 40-
60% chronic hepatitis and one-third of those 
cases will develop into progressive fibrosis and 
cirrhosis and hepatitis C becomes the main cause 
of liver transplants.2,3 In Japan, hepatitis C now 
has become the leading cause of hepatocellular 
carcinoma replacing hepatitis B and according to 
data in Centers for Disease Control and Prevention 
(CDC), there are approximately 8,000 – 10,000 
of deaths each year in the United States attributed 
to cirrhosis and malignancy associated with HCV. 
In Southeast Asia, the prevalence is about 2.2% 
or 32.3 million cases.3 The prevalence of HCV in 
Indonesia varies geographically as the country has 
extensive geographical diversity. A preliminary 
study of HCV in blood donors of various regions 
in Indonesia showed that the prevalence is about 
3.1-4%.3 New infections of HCV globally will occur 
in 3-4 million people each year with predominant 
HCV genotype 1, which is followed by genotype 2 
and 3. Other genotypes such as genotype 4, 5 and 
6 have specific geographical distribution. Most of 
acute HCV infections are asymptomatic and about 
70-80% cases will develop into chronic infection and 
progressive liver disease leading to liver cirrhosis and 
hepatocellular carcinoma.4 
The roles of immune system in chronic and 
acute hepatitis C are different and there are some 
hypothetical mechanisms that have tried to explain 
that generally, CD4+ and CD8+ are the important 
cellular immune system against the viral infection; 
however, they are not optimal for eradication of 
hepatitis C virus which may lead to persistent 
and chronic infection.5 The HCV-specific CD4+ 
and CD8+ T cells are predominantly found in the 
liver.6 Until now, few studies have been done that 
provide direct correlation between intrahepatic 
CD4+ and CD8+ and the process of liver damage 
in chronic hepatitis C, which have been shown as 
histopathological manifestation of hepatitis C. The 
results of those studies are still controversial. 
This study was aimed to evaluate the most 
dominant cellular immunity against the pathology of 
liver cell disorder. The study was also aimed to obtain 
the correlation between CD4+ and CD8+, either in 
hepatic lobules or portal tracts, and the severity of 
liver damage in patients with chronic hepatitis C. 
The study examined cellular immunity cells, which 
are regarded to have important role, i.e. the CD4+ 
and CD8+ count performed directly on liver biopsies 
available at the Division of Hepatology, Department 
of Internal Medicine and Anatomical Pathology 
Laboratory in Cipto Mangunkusumo Hospital. 
METHOD 
This study was a cross-sectional study with 
analytical technique to find mean differences 
between CD4+ counts of T helper lymphocytes 
and CD8+ cytotoxic T lymphocytes in portal tracts 
and hepatic lobules as well as the correlation with 
fibrosis and necroinflammatory grades in untreated 
hepatitis C patients. The population of study was 
patients infected with HCV who lived in Jakarta 
(pre-treatment) and visited Cipto Mangunkusumo 
Hospital to have antiviral treatment between January 
2008 and February 2010. Male or female patients 
aged between 18 and 70 years with positive HCV 
serology based on ELISA examination confirmed with 
polymerase chain reaction (PCR) were included in our 
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study. The exclusion criteria were history of alcohol 
consumption in the last 6 months period prior to liver 
biopsy, HIV infection, previous hepatitis C treatment 
(using interferon or ribavirin), having another liver 
disease other than chronic hepatitis C and those who 
refused to be participated in our study. 
The study was conducted at Division of Hepatology, 
Department of Internal Medicine and Department 
of Anatomical Pathology, Cipto Mangunkusumo 
Hospital between March 2010 and July 2010. 
We obtained data of liver biopsy speciments and 
laboratory data of patients with chronic hepatitis C 
who visited the Outpatient Clinic of Hepatology Unit 
at Cipto Mangunkusumo Hospital between January 
2008 and July 2010. 
Approximately 33 patients were participated in 
this study. The collection of baseline data included 
age, sex and basic history taking and physical 
examination according to the available forms. All 
patients had given their informed consent prior to 
the study. Paraffin blocks of patients’ liver biopsy 
were taken randomly according to the storing 
number at the Department of Anatomical Pathology. 
Each block was cut and made into two specimens 
for immunohistochemistry examination, stained 
with primer antibody of CD4+ and CD8+ and 
subsequently examined under light microscope with 
400 x magnification. Each count of CD4+ and CD8+ 
in five portal tracts and five hepatic lobules of each 
specimen were measured. Afterward, the total counts 
of both portal tracts and lobules were calculated for 
determining the mean value. The mean value of total 
counts in portal tracts and the lobules is intrahepatic 
CD4+ and CD8+ counts. Since CD4+ and CD8+ cells 
in liver tissues are predominated by specific cells, we 
hope that our techniques may represent the overall 
liver-specific CD4+ and CD8+ counts and minimize 
the possibility of uncounted CD4+ and CD8+. 
Statistical analysis using unpaired T-test for 
both groups (lobules and portal) for each CD4+ and 
CD8+ count was used to obtain mean differences 
of CD4+ and CD8+ counts between the lobules and 
portal tracts. Moreover, the correlation between 
portal and lobules CD4+ and CD8+ count and 
necroinflammatory grading as well as fibrosis 
staging in keeping with METAVIR was analyzed 
by using Spearman correlation test. Furthermore, to 
determine which variable of cellular immunity that 
may have role in liver damage process, the results 
of Spearman correlation test with p < 0.25 were 
included in multivariate analysis of multinomial 
logistic regression test. All analysis considered the 
value of 5% as significant and used 95% confidence 
interval. Data was processed using computer program 
of SPSS 17.
RESULTS 
Of 33 subjects included in the study, about 3 (9%) 
subjects were excluded since the results of their liver 
biopsies did not meet the minimal number requirement 
of portal tracts and lobules; therefore, only 30 subjects 
were analyzed at the end of the study. There were 
more female subjects, i.e. 17 people; while the age of 
subjects ranged between 24-69 years with median age 
of 58 years. Most subjects had genotype 1. Subject 
characteristics and laboratory results are presented in 
Table 1. 
Table 1. Subject characteristics (n = 30)
Characteristic n or median (range)
Age (year)
Sex
Male
Female
Genotype
1
2
3
4
Not available
Subtype
1a
1b
1a/1b
1c
2a/2c
3k
Not available
Complete peripheral blood
Hemoglobin (g/dL)
Hematocryte (%)
Leukocyte (x103/µL)
Thrombocyte (x103/µL)
AST (U/L)
ALT (U/L)
HCV-RNA (x 104 copy/mL) 
Degree of fibrosis (METAVIR)
F2
F3
F4
Degree of necroinflammatory (METAVIR)
A1
A2
A3
58 (24-69)
13
17
23
2
1
2
2
6
9
1
2
2
1
9
13.36 (1.51)
39.60 (5.25)
 5.5 (3.4-11.5)
 177 (78-403)
 89 (8-300)
 100.5 (9-415)
 56.5 (0.07-768)
11
9
10
1
12
17
The results of mean differences of CD4+ and 
CD8+ count in portal tracts and lobules along with 
its significant level are shown in Table 2; however 
the CD4+ and CD8+ counts, both in portal tracts 
and lobules, did not correlate with fibrosis or 
necroinflammatory grades (Table 3).
AST: aspartate transaminase; ALT: alanin transaminase; HCV-RNA: hepatitis 
C virus-ribonucleic acid
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Multivariate analysis was not performed since 
there was only one variable with p < 0.25 for each 
variable depended on fibrosis and necroinflamation, 
i.e. the correlation between the lobule CD8+ count and 
fibrosis staging (p = 0.06) and portal CD4+ count and 
necroinflammatory grading (p = 0.17).
DISCUSSION
The study was a cross-sectional study conducted 
in 30 patients with chronic hepatitis C and most of 
them were female subjects, i.e. 17 people aged 24-69 
years. Some studies have demonstrated that there is 
no significant difference on the prevalence of chronic 
hepatitis C between male and female subjects. This 
study found that predominant genotype was genotype 
1 with most subtype of 1b, which is consistent with 
the data of genotype distribution in Indonesia.7 HCV 
genotype has been frequently used as a significant 
epidemiologic marker of independent predictors to 
evaluate response to antiviral treatment. Worldwide 
studies have been conducted to retrieved data about 
hepatitis C patients with genotypes 1, 2, 3 and there 
are even special guidelines for determining the type of 
antiviral treatment and duration of treatment.8
The genotypes have been extensively studied to 
determine the persistence level of HCV infection. 
Amoroso et al have been specifically studied the 
role of HCV genotype on persistence level of HCV 
infection after initial exposure. They found that the 
evolution grade of becoming chronic infection after 
exposure of HCV was 92% when the subjects were 
exposed to genotype 1b, compared to 33-50% when 
they were exposed to other genotypes.9 Such results 
are consistent with our study that found subtype 1b as 
the most frequently found subtype. In our study, we 
found that there were greater number of subjects with 
more severe necroinflammatory grading since there 
may be a correlation between genotype 1b and the more 
severe grade of liver damage; however, it has not been 
specifically analyzed in our study. 
The study demonstrated significant mean differences 
(p = 0.002) between CD4+ and CD8+, either in the 
portal tracts or lobules (95% CI = 4.3-17.9; 95% 
CI = 15.4-35.6; p < 0.001). Canchis et al conducted 
a study on liver biopsies of 38 patients with chronic 
hepatitis C who had also had co-infection with 
HIV and 41 patients with monoinfection of chronic 
hepatitis C. They also evaluated CD4+ and CD8+ 
counts separately.10 However, the study did not analyze 
statistically whether there was significant difference 
between CD4+ and CD8+ counts in the portal and in 
the lobules. They had lesser number of CD4+ and CD8+ 
counts than our results, which may be due to separation 
of proliferative apoptosis T lymphocytes from the T 
lymphocytes stained with antibody against CD4+. 
A study conducted by Vrolijk et al in 17 subjects 
who had antiviral treatment of IFN-α2b (3 MU 3 x/
week) and ribavirin (1,000–1,200 mg/day) for 26 
weeks, evaluated the CD8+ count in portal tracts and 
lobules before and after treatment. The study found 
that the mean value of CD8+ counts before treatment 
in portal tracts and lobules were 47 (16.04%) dan 18 
(7.91%) with statistically significant mean difference 
between portal tracts and lobules (p < 0.001), i.e. 28.99 
(95% CI = 19.4-38.6).11 The results of their study are 
similar to our results. 
This study showed that there was greater mean 
value of CD8+ than CD4+ count and both counts are 
greater in portal tracts compared to those in the lobules. 
It suggests that CD8+ count in the liver is overall 
greater than CD4+ count. Different results have been 
Table 2. Mean difference of CD4+ and CD8+ count in portal tracts and lobules
 Average (SD) Δ mean (SE) 95% CI p*
CD4+ count (cell/LPB 
amount)
Portal
Lobulus
CD8+ count (cell/LPB 
amount)
Portal
Lobulus
31.41 (15.43)
20.31 (10.42)
59.25 (23.60)
33.72 (14.01)
11.1 (3.4)
25.5 (5.0)
4.3-17.9
15.4-35.6
0.002
< 0.001
*unpaired T-test; SD: standard deviation; SE: standard error; LPB: leukocyte-poor blood
Table 3. Correlation between portal tracts and lobules (CD4+ and 
CD8+ count) for the grades of fibrosis and necroinflammation 
Fibrosis Necroinflammatory
r p* r p*
CD4+
Portal 
Lobulus
0.02
-0.12
0.91
0.53
0.26
0.16
0.17
0.41
CD8+
Portal
Lobulus
-0.12
-0.35
0.53
0.06
-0.05
0.15
0.80
0.42
*Chi-square test
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found by Fiore et al who demonstrated that there was 
greater amount of CD4+ cells in portal and periportal 
area; while the CD8+ cells were predominantly found 
in lobules infiltrates. However, the study by Fiore et 
al also supported the hypothesis that the number of 
intrahepatic CD8+ is overall greater than CD4+.12 The 
greater number of CD4+ and CD8+ in portal tracts may 
be associated with diffuse inflammatory manifestation 
in portal and expanded portal area, which has been a 
characteristic histopathologic manifestation in chronic 
hepatitis C.13
In chronic infection, the uninfected surrounding 
hepatocytes will secrete cytokines such as IFN-γ and 
will modulate local immune responses, which may 
cause chronic inflammation. Lymphoid neogenesis, 
a developmental process of lymphoid follicles which 
will take place in portal area, is a characteristic 
manifestation of HCV chronic infection, which also 
explains the migration of T cells that have not been 
exposed to antigens from peripheral to the liver. It 
explains why the majority of CD4+ and CD8+ cells 
were in portal area. T cells from portal area will also 
migrate to the lobules and undergo recirculation process 
in the liver to maintain liver immunity through various 
mechanisms of apoptosis and proliferation; however, 
the mechanism explaining recirculation process from 
parenchymal tissue to local portal area associated with 
lymphoid tissue and its drainage process has not been 
defined yet.13
Another study as a comparison to this study is 
the study conducted by Viso et al which included 
all samples of the mildest to the most severe grades; 
however, they used the Ishak score for staging and 
grading system, which is quite different from our study 
which utilized the METAVIR score.14 
Statistically, only CD8+ count in the lobules that 
are likely to have weak negative correlation with liver 
fibrosis staging (r = -0.35; p = 0.06); while the CD4+ 
count in portal area was likely to have weak positive 
correlation with necroinflammatory grading (r = 0.26; 
p = 0.17). Overall, CD4+ and CD8+ were likely to have 
negative correlation with fibrosis staging and have 
positive correlation with necroinflammatory grading. 
Our study results are slightly different from the study 
conducted by Bonacini et al which demonstrated that 
CD8+ count had negative correlation with fibrosis 
score (r = -0.65), so did the CD4+ count in portal and 
periportal area.15 
Hepatocytes, cholangiocytes and sinusoid 
endothelial cells, stellate cells and Kuppfer cells 
express the Fas (CD95/Apo-1), which will be activated 
when it binds to FasL on the membrane or the soluble 
FasL. FasL is expressed on T lymphocytes cell and 
natural killer (NK) cells. The expression of FasL and 
Fas receptors will increase in patients with chronic liver 
disease. In chronic hepatitis C, the infected hepatocytes 
will undergo apoptosis and apoptosis process will be 
increasing and leading to fibrosis. Simultaneously, the 
apoptosis process facilitated by Fas will also increase 
in accordance with the increased inflammatory grades. 
The expression of Fas will continuously increase 
on infected hepatocytes which will lead to specific-
HCV T cells apoptosis, which also occurs through 
FasL expression. The theory can explain the overall 
tendency of negative correlation between CD4+ and 
CD8+ counts and fibrosis grades associated with the 
apoptosis process of T lymphocytes (CD4+ and CD8+), 
which also increased in response to increased FasL 
expression.16
In this study, CD4+ and CD8+ generally had 
positive correlation with necroinflammatory grading. It 
indicates that the greater amount of CD4+ and CD8+, 
the more severe necroinflammatory grade, which is 
directly associated with necroinflammation in the 
lobules. Such fact is consistent with the developing 
theory about the role of CD4+ and CD8+ on liver 
inflammation. CD4+ of T cells will be stimulated 
when recognizing viral peptide on class II HLA bound 
to APC, which subsequently will produce various 
cytokines i.e. IFN-γ,IL-2 and TNF-α which function 
as inflammatory mediators, activate CD8+ cells to 
produce IFN-γ and directly destroy the infected cells. 
Our study has also been consistent with other study 
reports that demonstrated direct correlation between 
CD8+ cells and the marker of hepatocellular damage 
(histological inflammatory activity and serum level of 
liver function test).17 
A study conducted by Roger et al in 28 patients 
with chronic hepatitis C may explain the positive 
correlation between CD4+ count in portal area and 
necroinflammatory grading. They studied the number 
of CD4+ cells which has undergone apoptosis in the 
liver correlated to histopathological manifestation of 
chronic hepatitis C based on METAVIR score. The 
study indicated negative correlation between the 
number of CD4+ undergoing apoptosis and METAVIR 
score. The greater CD4+ count experiencing apoptosis, 
the lower score of METAVIR is (in regard of 
the necroinflammatory grade). Efforts of CD4+ 
undergoing apoptosis, which occurs through Fas signal 
transmission process is regarded as protective value to 
reduce liver damage. It may explain the small number 
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of CD4+ count in portal area which may occur since 
most of CD4+ experiencing apoptosis and it is also 
associated with lesser METAVIR score.18
Further studies are necessary to find other factors 
other than CD4+ and CD8+ that may be directly 
involved with necroinflammation and liver fibrosis. 
The results of our study showed that there is lesser 
number of lymphocytes in more severe fibrosis, 
particularly the CD4+, which can be assumed that it has 
not been confirmed that T lymphocytes causes fibrosis 
but rather likewise. However, we have not provided 
statistic evidences in this study. 
The roles of immune system in chronic and 
acute hepatitis C are different. Several hypothetical 
mechanisms have tried to explain the cause of 
incapability of CD4+ and CD8+ to run their optimal 
function in eradicating the virus. The available IFN-
based standard treatment combined with ribavirin is 
necessary since there are many other factors excluding 
CD4+ and CD8+ are components of cellular immunity 
accounts for the pathogenesis of chronic hepatitis C. 
CONCLUSION 
There are greater CD4+ and CD8+ counts in portal 
area than hepatic lobules and the study showed more 
significant number of CD8+ than CD4+ both in portal 
tracts and hepatic lobules. There was no correlation 
between CD4+ or CD8+ in portal and the severity 
of liver damage in chronic hepatitis C. Although 
CD4+ and CD8+ have important role in pathogenesis 
of hepatitis C, but CD8+ and CD4+ T cells counts 
themselves both in portal tracts or hepatic lobules can 
not be used as predictors for liver damage. 
SUGGESTION 
Various other factors involved in the pathogenesis 
of hepatitis C excluding the cellular immunity need 
further studies to evaluate the possibility of correlation 
with fibrosis and liver necroinflammatory grades. 
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